Search Results - "OGNOSKIE, N"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation by Collins, Jr, R H, Shpilberg, O, Drobyski, W R, Porter, D L, Giralt, S, Champlin, R, Goodman, S A, Wolff, S N, Hu, W, Verfaillie, C, List, A, Dalton, W, Ognoskie, N, Chetrit, A, Antin, J H, Nemunaitis, J

    Published in Journal of clinical oncology (01-02-1997)
    “…Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed may attain complete remissions when treated with transfusions of leukocytes obtained…”
    Get more information
    Journal Article
  2. 2

    Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer by NEMUNAITIS, J, HOLMLUND, J. T, ECKHARDT, S. G, KRAYNAK, M, RICHARDS, D, BRUCE, J, OGNOSKIE, N, KWOH, T. J, GEARY, R, DORR, A, VON HOFF, D

    Published in Journal of clinical oncology (01-11-1999)
    “…To determine the maximum-tolerated dose (MTD) and pharmacologic behavior of ISIS 3521 (ISI 641A), an antisense phosphorothioate oligonucleotide to protein…”
    Get full text
    Journal Article
  3. 3

    Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma by Nemunaitis, J, Fong, T, Burrows, F, Bruce, J, Peters, G, Ognoskie, N, Meyer, W, Wynne, D, Kerr, R, Pippen, J, Oldham, F, Ando, D

    Published in Human gene therapy (20-05-1999)
    “…The purpose of this study was to determine the safety and antitumor activity of IFN-gamma retroviral vector in patients with advanced melanoma. Seventeen…”
    Get more information
    Journal Article
  4. 4

    Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma by Nemunaitis, J, Fong, T, Robbins, J M, Edelman, G, Edwards, W, Paulson, R S, Bruce, J, Ognoskie, N, Wynne, D, Pike, M, Kowal, K, Merritt, J, Ando, D

    Published in Cancer gene therapy (01-07-1999)
    “…Interferon-gamma (IFN-gamma) gene/retroviral vector cell vaccinations have generated protective responses from unmodified tumor cell challenges as well as a…”
    Get full text
    Journal Article
  5. 5

    Phase I trial of retroviral vector-mediated interferon (IFN)-gamma gene transfer into autologous tumor cells in patients with metastatic melanoma by Nemunaitis, J, Bohart, C, Fong, T, Meyer, W, Edelman, G, Paulson, R S, Orr, D, Jain, V, O'Brien, J, Kuhn, J, Kowal, K J, Burkeholder, S, Bruce, J, Ognoskie, N, Wynne, D, Martineau, D, Ando, D

    Published in Cancer gene therapy (01-09-1998)
    “…The purpose of this study was to determine the safety of treating melanoma patients with retroviral vector-mediated interferon (IFN)-gamma gene-transduced…”
    Get more information
    Journal Article
  6. 6

    Improved survival in patients with advanced colorectal carcinoma failing 5-fluorouracil who received irinotecan hydrochloride and have high intratumor C-fos expression by SINGH, A, TONG, A, OGNOSKIE, N, MEYER, W, NEMUNAITIS, J

    Published in American journal of clinical oncology (01-10-1998)
    “…This study determines the prognostic role of c-fos protein expression in patients with colon cancer who previously failed therapy with 5-fluorouracil (5-FU)…”
    Get full text
    Journal Article
  7. 7

    Prognostic Role of K-ras in Patients with Progressive Colon Cancer Who Received Treatment with Marimastat (BB2516) by Nemunaitis, John, Cox, John, Hays, Sarah, Meyer, Wally, Kebart, Richard, Ognoskie, Nadine, Courtney, Alice, Yu, Yaang, Rasmussen, Henrick, Tong, Alex

    Published in Cancer investigation (2000)
    “…Abstract We determined the prognostic role of K-ras mutation in tumor tissue of patients with refractory colon cancer who received Marimastat (BB2516). DNA was…”
    Get full text
    Journal Article